Poseida lines up another allogeneic CAR-T partner, allying with Astellas on solid tumors
Astellas will buy about 8.8% of Poseida Therapeutics for $25 million, and match that with a one-time payment for right of first refusal to license the biotech’s clinical-stage cell therapy for solid tumors, the companies said Monday morning.
Alongside the $50 million, Astellas nabs a board observer seat and can sit in on Poseida’s scientific advisory meetings.
The deal follows another allogeneic CAR-T pact that the San Diego-based biotech inked with Roche last August. That tie-up focused on hematological malignancies, which included $110 million upfront and an equal amount in near-term cash, for work on multiple assets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
